Navigation Links
Arpida Reports Interim Results for Six Months to 30 June 2008
Date:8/20/2008

James Bruno to Lead Arpida's North-American Commercial Operations

REINACH, Switzerland, August 20 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the six months ending 30 June 2008.
Highlights 2008 to date

Major pipeline progress:

- Regulatory filings for intravenous iclaprim in cSSSI submitted in

U.S.A. and Europe

- Enrolment in Phase II "intravenous-to-oral" switch trial with oral

iclaprim progresses well

- Enrolment in Phase II HAP/VAP/HCAP trial challenging

- Enrolment in Phase III trial with TLT approaches 50%

- Leadership change to enable Arpida to become a fully integrated

pharmaceutical company

- Raised CHF 19.6 million in a secondary offering in April 2008

- Cash and financial investments of CHF 67.9 million at 30 June 2008

CFO Harry Welten, MBA, commented: "Thanks to continued focus we have managed to keep spending in the first half of 2008 within the guidance given in March this year. Due to the build-up of commercial capabilities, we expect cash spending on operating activities in the second half of 2008 to be around CHF 4.5 million on average per month. Based on our financial position and iclaprim's advanced development status, we feel we are well-placed as we approach 2009, which we expect to be a launch year."

Dr Jürgen Raths, President and CEO, commented: "I am very pleased with the achievements in the year to date, not only in financial terms, but also in terms of development and regulatory progress. Our lead product candidate iclaprim is now under review at the major regulatory authorities on both sides of the Atlantic. We are very much looking forward to hearing from the U.S. authorities in January 2009. After more than 10 years of hard work, Arpida is getting very close to turning what used to be a promising compound into a promising drug, providing physicians with a potent new therapy in the fight against MRSA and other important pathogens."

Dr Raths added: "I am delighted that we have been able to attract James Bruno to join us and support us in developing and executing our commercial strategy. His proven track record of outstanding commercial leadership will be crucial as we add commercial competences."
The full, 12-page press release is available on http://www.arpida.com.

Contacts:

Arpida

Dr Jürgen Raths, President and CEO Tel.: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel.: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Tel.: +41-61-417-96-83

Communications


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... AxioMed will be presenting its ... meeting in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting ... to experience the simplicity of the surgical technique,” said Jake Lubinski, President of ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems ... Nipro will receive exclusive marketing and sales rights for all non-OEM Transonic products in ... patients in Japan, the new Nipro - Transonic JV is a natural next step ...
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, Inc. ... "Company"), announced that on January 14, 2017 the Board ... which the Company will terminate certain employees associated with ... Inc.  The Company commenced terminations on January 16, 2017 ... days.  The Company may pay severance benefits in certain ...
(Date:1/20/2017)... ... 20, 2017 , ... The two newest companies to join the University City ... spin out from The Wistar Institute, and Sanguis, launched by a trio of students ... , Vironika is developing a treatment for a chronic viral infection and its ...
Breaking Biology Technology:
(Date:1/4/2017)... 4, 2017  For the thousands of attendees at this year,s International ... connected health and biometric measurement devices and services, will be featuring its ... display in A&D Medical,s special CES Exhibit Suite , the new ... of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... VIEW, Calif. , Dec. 20, 2016  As part ... levels, 23andMe, the leading personal genetics company, recently released its ... Me . The book focuses on the topics of ... Next Generation Science Standards (NGSS) taught in elementary school classrooms ... second in a series by illustrator Ariana Killoran , ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
Breaking Biology News(10 mins):